Lifeway Foods, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016, compared with fiscal 2015. This is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text. Unless otherwise noted, financial amounts below are in millions of dollars.
Business context
Lifeway makes and sells fermented dairy and probiotic products, led by drinkable kefir. It reported one operating segment and derived substantially all revenue from fermented dairy products. About 99% of 2016 revenue came from products made at company facilities. Drinkable kefir excluding ProBugs generated $106.0 million, or 85.6% of sales. The company announced new cupped kefir and cheese products, probiotic supplements, and sparkling probiotic beverages; launches in late 2016 or early 2017 had no significant effect on 2016 results.
Financial performance and liquidity
| Metric | 2016 | 2015 | Change / context |
|---|---|---|---|
| Net sales | $123.879 | $118.587 | Up 4.5%; volume/mix contributed 3.0 percentage points and lower trade promotions 1.5 points |
| Gross profit / margin | $35.032 / 28.3% | $29.882 / 25.2% | Profit up 17.2%; margin improved 3.1 percentage points |
| Operating income / margin | $6.085 / 4.9% | $4.403 / 3.7% | Up 38.2% |
| Net income | $3.479 | $1.972 | EPS was $0.22 versus $0.12, basic and diluted |
| Operating cash flow | $5.104 | $6.745 | Lower mainly from working-capital timing |
| Capital expenditures | $3.237 | $1.995 | Higher investment in production equipment |
| Cash and cash equivalents | $8.812 | $5.646 | 2016 year-end balance |
| Total notes payable | $7.119 | $7.959 | $0.840 current; $6.279 long-term |
Gross-margin improvement reflected trade-promotion moderation and milk costs about 7% lower than in 2015. Selling expense rose 21.7% to $14.467 million, including higher advertising, compensation, and $0.600 million of related-party royalties. General and administrative expense increased 7.1% to $13.783 million. The effective tax rate declined to 38.3% from 50.6%, partly due to a favorable settlement of uncertain tax positions and lower nondeductible expenses. Net cash increased $3.166 million during 2016.
Year-end current assets were $28.204 million and current liabilities were $9.381 million, a current ratio of about 3.0. The $5 million revolving credit facility was unused at year-end and, unless renewed, was due to expire in July 2017. Management said it expected to fund foreseeable liquidity needs internally and anticipated compliance with loan agreements. The company reported no off-balance-sheet financing arrangements.
Material changes and notable items
- Sales growth was driven by private-label sales, higher organic volumes, new items, and reduced trade promotions; lower volumes of other branded drinkable kefir partly offset growth.
- Operating cash flow declined despite higher earnings, primarily because of working-capital effects, including unfavorable timing of payments to suppliers and service providers.
- The company liquidated its investment portfolio during the third quarter of 2016 to generate cash for general corporate purposes. There were no investments on the year-end 2016 balance sheet; 2015 included $2.091 million of investments and $0.513 million of certificates of deposit.
- The company repurchased 69,000 shares for $0.738 million in 2016; approximately $1.220 million remained authorized. It paid no dividends in 2016 or 2015.
- Two distributors accounted for approximately 23% of 2016 sales: United Natural Foods, Inc. (about 15%) and KEHE (about 8%). Together they represented about 25% of year-end receivables.
Outlook, risks, and governance
The filing provides no specific revenue, earnings, or margin guidance. Management discussed continued product innovation and exploring acquisitions to increase sales and leverage distribution, but cautioned that forward-looking statements are subject to risks. Key risks include competition and retailer pricing pressure, changing consumer preferences, milk and other input-cost volatility, product safety and recalls, supply-chain or facility disruptions, reliance on key customers and some sole-source co-packers, and variable-rate debt and covenant restrictions.
A material weakness in internal control over financial reporting remained as of December 31, 2016. Management cited deficiencies involving income-tax accounting, IT controls, and cash disbursements; management concluded disclosure controls and internal controls were ineffective. The independent auditor issued an adverse opinion on internal control, while giving an unqualified opinion on the consolidated financial statements. Management described remediation actions, but the auditor said there had not been sufficient time to establish that remediated controls operated effectively.
Related-party items included $1.000 million in consulting fees to the board chair, as in 2015, and $0.600 million in 2016 endorsement royalties to her. Senior executive participants earned $1.720 million in 2016 bonuses under a sales- and EBITDA-based incentive plan. The Smolyansky family owned approximately 49.8% of outstanding shares; Danone beneficially owned approximately 20% and held specified director nomination and anti-dilution rights.
Ordinary-course legal matters were disclosed; management said current accruals were not material and expected no material adverse effect, while noting that outcomes and potential losses could not be predicted with reasonable certainty. The filing also identified risks from extensive food, organic-product, environmental, and workplace regulation.
Important facts for investors to verify
- Whether the company remediated the material weakness and whether controls were subsequently shown to operate effectively.
- Renewal or replacement of the revolving credit facility due to expire in July 2017, and continued compliance with loan covenants and debt-service requirements.
- Whether gross-margin gains from lower milk costs and reduced promotions are sustainable as input prices, promotions, and product mix change.
- Sales trends for branded kefir versus private-label and organic products, and the performance and costs of newly launched products.
- Customer concentration, receivable exposure, and continuity of supply from key co-packers, including any sole-source arrangements.
- The terms, ongoing cost, and governance oversight of related-party consulting and endorsement arrangements and executive incentives.